Overview

Denosumab for Smoldering Multiple Myeloma

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety and tolerability of denosumab in smoldering multiple myeloma subjects as well to see if denosumab can reduce subjects' risk of getting multiple myeloma.

Phase:

Phase 2

Details

Lead Sponsor:

University of Rochester

Collaborator:

Amgen

Treatments:

Denosumab